Esta página aún no ha sido traducida al español. Mientras tanto, te mostramos la versión en inglés con la navegación y pie de página en español. El contenido completo en español estará disponible pronto.
Evidence-based research profiles for anabolic-androgenic steroids, selective estrogen receptor modulators, aromatase inhibitors, and post-cycle therapy compounds. Bloodwork monitoring context included. For research use only.
Monitor liver enzymes (AST/ALT), lipids (LDL/HDL), hormones (testosterone, LH, FSH, estradiol), and hematocrit. Our Bloodwork Interpreter covers 27 markers with AAS-specific context for each.
Check AAS + SERM + peptide stacks for conflicts. 25+ named rules, 6 risk dimensions. No login.
Long-acting testosterone ester (7-day half-life) studied as the reference standard for androgen research. Mechanism: androgen receptor agonism. Aromatizes to estradiol via CYP19A1. Most widely used base compound in AAS research.
Read research profile → Injectable AASEquivalent to enanthate (8–12 day half-life) with identical mechanism. Studied for TRT protocols and HPA axis regulation. Commonly used as interchangeable research alternative to enanthate due to comparable pharmacokinetics.
Read research profile → Injectable AAS19-nortestosterone derivative (Deca-Durabolin) with reduced androgenic activity. Studied for anabolic effects, joint lubrication research, and progestin receptor activity. Half-life: 6–12 days. Low aromatization.
Read research profile → Injectable AASTestosterone-derived compound (Equipoise) studied for sustained anabolic activity and erythropoiesis stimulation via EPO upregulation. Half-life: 14 days. ~50% aromatization rate vs testosterone.
Read research profile → Injectable AAS19-nortestosterone derivative with ~5× androgen receptor affinity of testosterone. Does not aromatize. Strong progestin activity. Studied for nitrogen retention and IGF-1 upregulation mechanisms. Half-life: 3 days.
Read research profile →DHT-derivative studied for anti-estrogenic activity via aromatase inhibition at androgen receptor level. Does not aromatize. Researched for its SHBG-binding interactions and free androgen index effects.
Research profile coming →DHT-derived oral with low androgenicity and mild hepatotoxicity vs other 17α-alkylated compounds. Studied for nitrogen retention, SHBG reduction, and IGF-1 stimulation. Half-life: 9–10 hours. FDA-approved for muscle wasting research.
Read research profile →17α-alkylated DHT-derived compound studied for SHBG-binding reduction and free testosterone elevation. Known for SHBG displacement effects. Moderate hepatotoxicity. Veterinary and human pharmaceutical history.
Research profile coming →Fast-acting 17α-alkylated testosterone derivative. Studied for rapid nitrogen retention and protein synthesis effects. Significant aromatization. Half-life: 3–6 hours. First widely researched oral AAS.
Read research profile →DHT-derived 17α-alkylated compound studied for erythropoiesis stimulation and hematocrit effects. One of the most potent oral AAS by nitrogen retention metrics. Significant hepatotoxicity risk in research contexts.
Research profile coming →Chlorinated Dianabol derivative with reduced aromatization and androgenicity. Studied for SHBG reduction and protein synthesis with longer half-life (16 hours). East German research compound; detected in doping studies.
Research profile coming →First-generation SERM studied for estrogen receptor antagonism in breast tissue and agonism in uterus/bone. Used in PCT research to restore LH/FSH pulsatility. Mechanism: competitive ER binding. FDA-approved oncology drug.
Read research profile → SERMMixed estrogen receptor agonist/antagonist studied for hypothalamic feedback disruption and gonadotropin release. Two isomers: zuclomiphene (agonist) and enclomiphene (antagonist). PCT and male hypogonadism research applications.
Read research profile → SERMPure trans-clomiphene isomer without the estrogenic zuclomiphene component. Studied for hypothalamic-pituitary-gonadal axis restoration with cleaner LH/FSH stimulation vs racemic Clomid. Phase 3 clinical research for hypogonadism.
Read research profile → SERMSecond-generation SERM studied for gynecomastia treatment in research contexts. Superior ER antagonism in breast tissue vs Tamoxifen for some glandular tissue studies. FDA-approved for osteoporosis. No uterine stimulation.
Read research profile → SERMSecond-generation non-steroidal SERM with mixed agonist/antagonist profile. CYP3A4 metabolism (not CYP2D6-dependent) — more predictable efficacy. Favorable uterine safety profile vs tamoxifen in extended use. FDA-approved for metastatic breast cancer.
Read research profile →Non-steroidal reversible CYP19A1 (aromatase) inhibitor. Studied for estradiol suppression in androgen research protocols. FDA-approved for breast cancer. Mechanism: competitive aromatase enzyme binding. Half-life: ~46 hours.
Read research profile → Aromatase InhibitorSteroidal irreversible aromatase inactivator. Studied for permanent aromatase enzyme binding without rebound estradiol elevation. FDA-approved. Mildly androgenic due to androstane scaffold. Half-life: ~24 hours.
Read research profile → Aromatase InhibitorNon-steroidal aromatase inhibitor with highest potency among triazole AIs. Studied for near-complete estrogen suppression (up to 99%). FDA-approved. Used in gynecomastia and estrogen-related research. Half-life: ~48 hours.
Read research profile →LH analog studied for testicular Leydig cell stimulation and spermatogenesis maintenance. Mimics LH/FSH action on gonadal axis. Used in PCT research to preserve testicular volume and restore testosterone production during/after cycles.
Read research profile → PCT / SupportBile acid studied for hepatoprotective activity against 17α-alkylated AAS hepatotoxicity. Mechanism: mitochondrial membrane stabilization, ER stress reduction. Also studied for cholestasis and neurodegenerative research contexts.
Read research profile → PCT / SupportGlutathione precursor studied for hepatoprotection via oxidative stress reduction. Standard liver support compound in AAS research contexts. Also researched for respiratory, psychiatric, and acetaminophen toxicity applications.
Read research profile → PCT / SupportDopamine D2/D3 agonist studied for prolactin suppression in 19-nortestosterone (nandrolone, trenbolone) research protocols. FDA-approved for hyperprolactinemia. Mechanism: inhibits pituitary prolactin secretion. Half-life: 63–68 hours.
Read research profile → PCT / SupportOral 1α-methyl DHT derivative studied for SHBG displacement and free testosterone elevation in AAS research. Mildly androgenic, non-aromatizable, not hepatotoxic via 17α-alkylation. Researched for androgenic support and male fertility. Half-life: ~12 hours.
Read research profile →Dual 5α-reductase inhibitor (types 1 + 2) studied for DHT reduction in androgen-sensitive tissue research. ~90% DHT suppression vs finasteride's ~70%. Researched for scalp androgen receptor interaction during AAS cycles. Half-life: ~5 weeks.
Research profile coming →The Bloodwork Interpreter covers liver function (AST, ALT, GGT, bilirubin), lipid panel (LDL, HDL, triglycerides), hormones (Total T, Free T, LH, FSH, estradiol, prolactin, SHBG), kidney markers, CBC, and more — all with compound-specific context.